Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
18.61
USD
-0.24 (-1.27%)
Official Closing Price
Updated: 7:16 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Atara Biotherap
< Previous
1
2
3
4
5
6
7
Next >
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress
May 19, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid...
From
Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 18, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid...
From
Business Wire News Releases
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer
May 15, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid...
From
Business Wire News Releases
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
May 14, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...
From
Business Wire News Releases
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
May 11, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...
From
Business Wire News Releases
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
May 06, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...
From
Business Wire News Releases
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
April 30, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
Business Wire News Releases
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
April 30, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
Business Wire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 22, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
Business Wire News Releases
Company Profile for Atara Biotherapeutics, Inc.
April 02, 2020
Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology...
Tags
Atara Biotherapeutics, Inc.
From
Business Wire News Releases
Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
April 02, 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
Business Wire News Releases
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
February 27, 2020
Company to host conference call today at 8:00 a.m. EST
From
GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 21, 2020
From
GlobeNewswire News Releases
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
February 20, 2020
From
GlobeNewswire News Releases
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
February 19, 2020
Live Conference Call and Webcast at 8:00 a.m. EST
From
GlobeNewswire News Releases
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
February 05, 2020
From
GlobeNewswire News Releases
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
January 12, 2020
From
GlobeNewswire News Releases
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lympho
December 09, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
November 26, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
November 07, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoprol
November 06, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
October 30, 2019
Live Conference Call and Webcast at 8:00 a.m. EST
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Executive Departures
October 25, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
September 13, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
September 09, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
August 28, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
August 08, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
August 01, 2019
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
July 18, 2019
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Proposed Offering of Common Stock
July 18, 2019
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.